Michele Maio
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 191
- Cancer Immunotherapy and Biomarkers 122
- CAR-T cell therapy research 64
- Cutaneous Melanoma Detection and Management 23
- Immunology 131
- Immunotherapy and Immune Responses 104
- T-cell and B-cell Immunology 31
- Immune Cell Function and Interaction 29
- Co-authors
- Maresa Altomonte (77 shared papers)Ester Fonsatti (58 shared papers)Jedd D. Wolchok (16 shared papers)Anna Maria Di Giacomo (62 shared papers)Luca Sigalotti (53 shared papers)Paolo A. Ascierto (46 shared papers)Célèste Lebbé (13 shared papers)Jeffrey S. Weber (14 shared papers)
- Journals
- Annals of Oncology (54 papers)Journal of Translational Medicine (21 papers)European Journal of Cancer (20 papers)Cancer Immunology Immunotherapy (20 papers)Clinical Cancer Research (18 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Michele Maio
383 papers receiving 67.6k citations
Michele Maio's Hit Papers
Peers
Comparison fields: 5 of 175
- Oncology 43.6k
- Immunology 21.2k
- Cancer Research 4.9k
- Molecular Biology 20.3k
- Pulmonary and Respiratory Medicine 8.2k
Countries citing papers authored by Michele Maio
This map shows the geographic impact of Michele Maio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Maio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Maio more than expected).
Fields of papers citing papers by Michele Maio
This network shows the impact of papers produced by Michele Maio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Maio. The network helps show where Michele Maio may publish in the future.
Co-authors
The 25 scholars most cited alongside Michele Maio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 393 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 2 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6388 |
| 3 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Hit paper breakdown → | 2014 | 4679 |
| 4 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 5 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3746 |
| 6 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 7 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Hit paper breakdown → | 2009 | 2660 |
| 8 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2015 | 2293 |
| 9 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Hit paper breakdown → | 2017 | 1783 |
| 10 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1697 |
| 11 | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study Hit paper breakdown → | 2018 | 1627 |
| 12 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1503 |
| 13 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2014 | 1259 |
| 14 | Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours Hit paper breakdown → | 2013 | 1151 |
| 15 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy Hit paper breakdown → | 2016 | 1099 |
| 16 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2015 | 1016 |
| 17 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Hit paper breakdown → | 2014 | 836 |
| 18 | High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients Hit paper breakdown → | 2009 | 827 |
| 19 | Cancer classification using the Immunoscore: a worldwide task force Hit paper breakdown → | 2012 | 687 |
| 20 | Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Hit paper breakdown → | 2013 | 672 |
About Michele Maio
Michele Maio is a scholar working on Oncology, Immunology, Molecular Biology, Immunology and Allergy and Pulmonary and Respiratory Medicine, having authored 393 papers that have together received 69.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (122 papers), Immunotherapy and Immune Responses (104 papers), CAR-T cell therapy research (64 papers), Melanoma and MAPK Pathways (46 papers), T-cell and B-cell Immunology (31 papers), Immune Cell Function and Interaction (29 papers), Cutaneous Melanoma Detection and Management (23 papers) and Epigenetics and DNA Methylation (23 papers). The work is most often cited by research in Oncology (43.6k citations), Immunology (21.2k citations), Cancer Research (4.9k citations), Molecular Biology (20.3k citations) and Pulmonary and Respiratory Medicine (8.2k citations). Michele Maio has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Maresa Altomonte, Ester Fonsatti, Jedd D. Wolchok, Anna Maria Di Giacomo, Luca Sigalotti, Paolo A. Ascierto, Célèste Lebbé, Jeffrey S. Weber, Luana Calabrò and Sandra Coral. Their work appears in journals such as Annals of Oncology, Journal of Translational Medicine, European Journal of Cancer, Cancer Immunology Immunotherapy and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.